SEC Form 4 · accession 0001177648-18-000026
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay R. Luly
Officer — President and CEO · Director
Period of report
May 16, 2018
Accepted (ET)
May 18, 2018 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | May 16, 2018 | S | 14,032 | $105.8233 | D | 638,994 | D | |
| Common StockF3 | May 17, 2018 | S | 10,968 | $105.8299 | D | 628,026 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.75 to $106.00, inclusive.
- F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.75 to $106.35, inclusive.